10. Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, et al. (2008) Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 213: 448–455. 11. Itoh T, Satou T, Nishida S, Tsubaki M, Hashimoto S, et al. (2009) The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury. Neurotox Res 16: 378–389. 12. Dohi K, Satoh K, Mihara Y, Nakamura S, Miyake Y, et al. (2006) Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury. J Neurotrauma 23: 1591–1599. 13. Higgins GC, Beart PM, Shin YS, Chen MJ, Cheung NS, et al. (2010) Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. J Alzheimers Dis 20 Suppl 2: S453–473. 14. Yuan WJ, Yasuhara T, Shingo T, Muraoka K, Agari T, et al. (2008) Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci 9: 75. 15. Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T (2007) Edaravone (3- methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J Pharmacol Exp Ther 322: 274–281. 16. Alam M, Danysz W, Schmidt WJ, Dekundy A (2009) Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Toxicol Appl Pharmacol 240: 198–207. 17. Kim ST, Son HJ, Choi JH, Ji IJ, Hwang O (2010) Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson’s disease. Brain Res 1306C: 176–183. 18. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, et al. (2009) WIN55,212- 2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur J Neurosci 29: 2177–2186. 19. Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, et al. (2007) Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson’s disease. J Neurosci 27: 6701–6711. 20. Beurrier C, Lopez S, Revy D, Selvam C, Goudet C, et al. (2009) Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 23: 3619–3628. 21. Dreiem A, Myhre O, Fonnum F (2002) Relationship between lipophilicity of C6- 10 hydrocarbon solvents and their ROS-inducing potency in rat cerebellar granule cells. Neurotoxicology 23: 701–709. 22. Rammal H, Bouayed J, Younos C, Soulimani R (2008) Evidence that oxidative stress is linked to anxiety-related behaviour in mice. Brain Behav Immun 22: 1156–1159. 23. Liu S, Xu L, Zhang T, Ren G, Yang Z (2010) Oxidative stress and apoptosis induced by nanosized titanium dioxide in PC12 cells. Toxicology 267: 172–177. 24. Xiong N, Huang J, Zhang Z, Xiong J, Liu X, et al. (2009) Stereotaxical Infusion of Rotenone: A Reliable Rodent Model for Parkinson’s Disease. PLoS One 4: e7878. 25. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE (2005) Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 23: 220–229. 26. Xiong N, Cao X, Zhang Z, Huang J, Chen C, et al. (2010) Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone- induced hemiparkinsonian rats. Biol Blood Marrow Transplant 16: 1519–1529. 27. Xiong N, Zhang Z, Huang J, Chen C, Jia M, et al. (2011) VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson’s disease. Gene Ther 18: 394–402. 28. Zuber B, Nikonenko I, Klauser P, Muller D, Dubochet J (2005) The mammalian central nervous synaptic cleft contains a high density of periodically organized complexes. Proc Natl Acad Sci U S A 102: 19192–19197. 29. Lin Z, Zhao Y, Chung CY, Zhou Y, Xiong N, et al. (2010) High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. FASEB J 24: 2191–2200. 30. Xiong N, Huang J, Chen C, Zhao Y, Zhang Z, et al. (2011) Dl-3-n- Butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson’s Disease. Neurobiol Aging;doi:10.1016/j.neurobiolaging. 2011.03.007. Edaravone Guards Dopamine Neurons 31. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, et al. (2002) An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered alpha- synuclein metabolism and oxidative damage. J Neurosci 22: 7006–7015. 32. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, et al. (2003) Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci 23: 10756–10764. 33. Feng Y, Liang ZH, Wang T, Qiao X, Liu HJ, et al. (2006) alpha-Synuclein redistributed and aggregated in rotenone-induced Parkinson’s disease rats. Neurosci Bull 22: 288–293. 34. Alam M, Schmidt WJ (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136: 317–324. 35. Alam M, Schmidt WJ (2004) L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav Brain Res 153: 439–446. 36. Rajesh KG, Sasaguri S, Suzuki R, Maeda H (2003) Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression. Am J Physiol Heart Circ Physiol 285: H2171–2178. 37. Amemiya S, Kamiya T, Nito C, Inaba T, Kato K, et al. (2005) Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur J Pharmacol 516: 125–130. 38. Xiao B, Bi FF, Hu YQ, Tian FF, Wu ZG, et al. (2007) Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats. Neurotox Res 12: 155–162. 39. Qi X, Okuma Y, Hosoi T, Nomura Y (2004) Edaravone protects against hypoxia/ischemia-induced endoplasmic reticulum dysfunction. J Pharmacol Exp Ther 311: 388–393. 40. Kawasaki T, Kitao T, Nakagawa K, Fujisaki H, Takegawa Y, et al. (2007) Nitric oxide-induced apoptosis in cultured rat astrocytes: protection by edaravone, a radical scavenger. Glia 55: 1325–1333. 41. Chen H, Wang S, Ding JH, Hu G (2008) Edaravone protects against MPP+ -induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway. J Neurochem 106: 2345–2352. 42. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, et al. (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19: 1285–1296. 43. Lin Z, Walther D, Yu XY, Li S, Drgon T, et al. (2005) SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet 14: 1393–1404. 44. Lin Z, Zhao Y, Chung CY, Zhou Y, Xiong N, et al. (2010) High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. FASEB J. 45. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, et al. (2010) In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 51: 223–228. 46. Watabe M, Nakaki T (2008) Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Mol Pharmacol 74: 933–940. 47. Chen CX, Huang SY, Zhang L, Liu YJ (2005) Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells. Neurobiol Dis 19: 419–426. 48. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B (2006) Gain-of- function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 15: 299–305. 49. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, et al. (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62: 218–229. 50. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11: 1214–1221. 51. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, et al. (2008) Dopamine-modified alpha-synuclein blocks chaperone-mediated autoph- agy. J Clin Invest 118: 777–788. 52. Itoh Y, Takaoka R, Ohira M, Abe T, Tanahashi N, et al. (2006) Reactive oxygen species generated by mitochondrial injury in human brain microvessel endothelial cells. Clin Hemorheol Microcirc 34: 163–168. 53. Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, et al. (2002) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59: 1161–1169. PLoS ONE | www.plosone.org 11 June 2011 | Volume 6 | Issue 6 | e20677